Commercial Launch Arch has recently launched AC5 Advanced Wound System and AC5 Topical Hemostat in key markets and is actively showcasing at major wound care events, presenting a prime window to pursue hospital systems, WOC teams, and wound care centers for adoption and bundled procurement.

Clinical & Payer Strategy The company has pursued multi-site clinical studies and payor-focused initiatives to differentiated AC5, suggesting sales opportunities with reference sites, case studies, and payer adoption programs targeting chronic wound care and surgical hemostasis.

Strategic Partnerships Existing distribution alliance with Centurion Therapeutics and ongoing collaborations indicate a readiness to scale through partner networks; repurposing or expanding these partnerships could accelerate sales in hospitals, ambulatory surgery centers, and wound care centers.

Regulatory Footprint Regulatory clearances for AC5 products in the US and Europe create a dual-market path; sales teams can target cross-border procurement, national health systems, and regional distributors seeking FDA/CE-marked wound care solutions.

Tech & Data Upsell Arch’s self-assembling barrier technology and demonstrated clinical benefits offer a value proposition for expanding into adjacent wound care, sealant, and hemostasis segments; identify opportunities to upsell to multi-product bundles and HPB (high-value product) programs with care pathways.